Clinical trials: Minimal Residual Disease Persistence
Acute Myeloid Leukemia
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
The VERDI study is an investigator-initiated, multicenter, multicohort, phase II trial with combination of venetoclax + azacitidine for patients treated for AML under according to an intensive chemotherapy protocol (CETLAM-20)…
- Trial name
- VERDI (NCT06668558)
- Testing
- Azacitidine (AZA), Venetoclax
- Where
- 14 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Gastric Cancer, HER2-positive Gastric Cancer
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
TRINITY is designed as a multicentre, randomized, open-label, interventional phase II study aimed at investigating the activity, efficacy and safety of trastuzumab-deruxtecan (T-DXd) plus capecitabine/5-fluorouracil as a…
- Trial name
- TRINITY (NCT06253650)
- Testing
- Experimental, Control
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission.
- Conditions
- Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder, Acute Myeloid Leukemia
- Trial name
- NCT04062266
- Testing
- Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy
Surgical resection is curative for 75% of stage II and 50% of stage III colon cancer patients. The magnitude of benefit of adjuvant chemotherapy in terms of disease-free (DFS) and overall survival (OS) varies according to TNM…
- Trial name
- ERASE-TMZ (NCT05031975)
- Testing
- Irinotecan, Temozolomide
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano